{"title":"美达以31亿美元收购Rottapharm宣告独立","authors":"Heather Cartwright","doi":"10.3833/pdr.v2014i9.2060","DOIUrl":null,"url":null,"abstract":"Having rejected two takeover bids from Mylan earlier in 2014, Sweden’s Meda has agreed to acquire the Italian speciality pharmaceutical company Rottapharm Madaus for a total consideration of SEK21.2 B (US$3.1 B), including net debt of SEK2.8 B (US$407 M). The deal comes only weeks after family owned Rottapharm withdrew a planned IPO citing unfavourable market conditions. The acquisition, the largest in Meda’s history, will bolster the company’s consumer healthcare business and increase its emerging market revenues by 50%.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"172 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meda Asserts Independence with US$3.1 B Rottapharm Acquisition\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2014i9.2060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Having rejected two takeover bids from Mylan earlier in 2014, Sweden’s Meda has agreed to acquire the Italian speciality pharmaceutical company Rottapharm Madaus for a total consideration of SEK21.2 B (US$3.1 B), including net debt of SEK2.8 B (US$407 M). The deal comes only weeks after family owned Rottapharm withdrew a planned IPO citing unfavourable market conditions. The acquisition, the largest in Meda’s history, will bolster the company’s consumer healthcare business and increase its emerging market revenues by 50%.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"172 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-11-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2014i9.2060\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2014i9.2060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Meda Asserts Independence with US$3.1 B Rottapharm Acquisition
Having rejected two takeover bids from Mylan earlier in 2014, Sweden’s Meda has agreed to acquire the Italian speciality pharmaceutical company Rottapharm Madaus for a total consideration of SEK21.2 B (US$3.1 B), including net debt of SEK2.8 B (US$407 M). The deal comes only weeks after family owned Rottapharm withdrew a planned IPO citing unfavourable market conditions. The acquisition, the largest in Meda’s history, will bolster the company’s consumer healthcare business and increase its emerging market revenues by 50%.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
